title: Concurrent presentation of erythrocytic and megakaryocytic aplasia.
abstract: A case of a patient presenting with idiopathic concurrent erythrocytic and megakaryocytic aplasia is reported. The patient's response to immunosuppressive therapy and her bone marrow pathology clearly suggest an immune mechanism. Based on the lack of suppression of erythroid colony growth, several mechanisms are postulated. Well-established molecular and genetic evidence, along with clinical observations, suggests that a relationship exists between the erythrocytic and megakaryocytic cell lines. This may be related to a common bipotential stem cell or common cell surface markers. This case provides strong clinical evidence to support this relationship.
authors.affiliation: Division of Hematology/Oncology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, USA.
authors.forename: B F
authors.initials: BF
authors.lastname: Canavan
authors.forename: R D
authors.initials: RD
authors.lastname: Huhn
authors.forename: H C
authors.initials: HC
authors.lastname: Kim
authors.forename: M
authors.initials: M
authors.lastname: Kosmin
authors.forename: W
authors.initials: W
authors.lastname: Sheay
authors.forename: P
authors.initials: P
authors.lastname: Saidi
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D001327:Autoimmune Diseases / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology*; D019070:Cell Lineage; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D015672:Erythroid Precursor Cells / Q000473:pathology*; D005260:Female; D006410:Hematopoiesis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D018937:Hepatitis C Antibodies / Q000032:analysis; D006801:Humans; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000032:analysis; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008533:Megakaryocytes / Q000473:pathology*; D016732:Parvovirus B19, Human / Q000276:immunology; D017713:Platelet Transfusion; D011241:Prednisone / Q000627:therapeutic use; D012010:Red-Cell Aplasia, Pure / Q000150:complications* / Q000276:immunology / Q000628:therapy; D013921:Thrombocytopenia / Q000150:complications* / Q000276:immunology / Q000628:therapy; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D014750:Vincristine; D016572:Cyclosporine; D003520:Cyclophosphamide; D011241:Prednisone